Cargando…

Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study

PURPOSE: This study was designed to test the hypothesis that exposure to ivermectin in early disease prevents mortality due to COVID-19. A secondary objective was to see if the drug has any impact on the length of hospital stay among the survivors. METHODS: It was a hospital-based retrospective case...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirti, Ravi, Ranjan, Alok, Porel, Rajdeep, Agarwal, Ketan, Tahaseen, Shaik M., Shyama, Kumar, Anjani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071928/
https://www.ncbi.nlm.nih.gov/pubmed/37025225
http://dx.doi.org/10.4103/jfmpc.jfmpc_1163_22
_version_ 1785019287366270976
author Kirti, Ravi
Ranjan, Alok
Porel, Rajdeep
Agarwal, Ketan
Tahaseen, Shaik M.
Shyama,
Kumar, Anjani
author_facet Kirti, Ravi
Ranjan, Alok
Porel, Rajdeep
Agarwal, Ketan
Tahaseen, Shaik M.
Shyama,
Kumar, Anjani
author_sort Kirti, Ravi
collection PubMed
description PURPOSE: This study was designed to test the hypothesis that exposure to ivermectin in early disease prevents mortality due to COVID-19. A secondary objective was to see if the drug has any impact on the length of hospital stay among the survivors. METHODS: It was a hospital-based retrospective case-control study conducted at a tertiary teaching hospital in India. All patients with a diagnosis of COVID-19 who were admitted between 1(st) April and 15(th) May 2021 and received inpatient care were included. Important variables like demographic details, dates of admission and discharge or death, symptoms at the time of admission, comorbidities, severity of illness at the time of admission, whether ivermectin was administered or not during the course of the illness and other treatments received as part of the standard of care were retrieved from the medical records. RESULTS: Of the 965 patients who received inpatient care, 307 died during their hospital stay while 658 were successfully discharged. The proportion of cases treated with ivermectin was 17.26% among the non-survivors (53/307) and 17.93% among the survivors (118/658). The effect was statistically insignificant (crude OR = 0.954; 95% CI: 0.668–1.364, P = 0.80). Among the survivors, the median length of stay was 11 days for patients who received ivermectin (IQR: 7–15) as well as for those who did not (IQR: 7–16). CONCLUSION: This study did not show any effect of ivermectin on in-patient mortality in patients with COVID-19 and there was no effect of the drug on the length of hospital stay among the survivors.
format Online
Article
Text
id pubmed-10071928
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-100719282023-04-05 Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study Kirti, Ravi Ranjan, Alok Porel, Rajdeep Agarwal, Ketan Tahaseen, Shaik M. Shyama, Kumar, Anjani J Family Med Prim Care Original Article PURPOSE: This study was designed to test the hypothesis that exposure to ivermectin in early disease prevents mortality due to COVID-19. A secondary objective was to see if the drug has any impact on the length of hospital stay among the survivors. METHODS: It was a hospital-based retrospective case-control study conducted at a tertiary teaching hospital in India. All patients with a diagnosis of COVID-19 who were admitted between 1(st) April and 15(th) May 2021 and received inpatient care were included. Important variables like demographic details, dates of admission and discharge or death, symptoms at the time of admission, comorbidities, severity of illness at the time of admission, whether ivermectin was administered or not during the course of the illness and other treatments received as part of the standard of care were retrieved from the medical records. RESULTS: Of the 965 patients who received inpatient care, 307 died during their hospital stay while 658 were successfully discharged. The proportion of cases treated with ivermectin was 17.26% among the non-survivors (53/307) and 17.93% among the survivors (118/658). The effect was statistically insignificant (crude OR = 0.954; 95% CI: 0.668–1.364, P = 0.80). Among the survivors, the median length of stay was 11 days for patients who received ivermectin (IQR: 7–15) as well as for those who did not (IQR: 7–16). CONCLUSION: This study did not show any effect of ivermectin on in-patient mortality in patients with COVID-19 and there was no effect of the drug on the length of hospital stay among the survivors. Wolters Kluwer - Medknow 2023-01 2023-02-15 /pmc/articles/PMC10071928/ /pubmed/37025225 http://dx.doi.org/10.4103/jfmpc.jfmpc_1163_22 Text en Copyright: © 2023 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kirti, Ravi
Ranjan, Alok
Porel, Rajdeep
Agarwal, Ketan
Tahaseen, Shaik M.
Shyama,
Kumar, Anjani
Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study
title Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study
title_full Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study
title_fullStr Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study
title_full_unstemmed Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study
title_short Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study
title_sort association between ivermectin treatment and mortality in covid-19: a hospital-based case-control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071928/
https://www.ncbi.nlm.nih.gov/pubmed/37025225
http://dx.doi.org/10.4103/jfmpc.jfmpc_1163_22
work_keys_str_mv AT kirtiravi associationbetweenivermectintreatmentandmortalityincovid19ahospitalbasedcasecontrolstudy
AT ranjanalok associationbetweenivermectintreatmentandmortalityincovid19ahospitalbasedcasecontrolstudy
AT porelrajdeep associationbetweenivermectintreatmentandmortalityincovid19ahospitalbasedcasecontrolstudy
AT agarwalketan associationbetweenivermectintreatmentandmortalityincovid19ahospitalbasedcasecontrolstudy
AT tahaseenshaikm associationbetweenivermectintreatmentandmortalityincovid19ahospitalbasedcasecontrolstudy
AT shyama associationbetweenivermectintreatmentandmortalityincovid19ahospitalbasedcasecontrolstudy
AT kumaranjani associationbetweenivermectintreatmentandmortalityincovid19ahospitalbasedcasecontrolstudy